To further examine whether ARVC disease progression could be slowed down or attenuated by restoration of PKP2 expression after overt structural changes, the therapeutic mode of treatment, we dosed animals via retro-orbital injection of AAV9:mPkp2 at 1E14 vg/kg at 2.5 weeks after cardiac deletion of Pkp2 (Fig. 6a). Here, PKP2 is linked to Arrhythmogenic right ventricular dysplasia.